Resolving the pharmacological redox-sensitivity of SARS-CoV-2 PLpro in drug repurposing screening enabled identification of the competitive GRL-0617 binding site inhibitor CPI-169
Maria Kuzikov, Stefano Morasso, Jeanette Reinshagen, Markus Wolf, Vittoria Monaco, Flora Cozzolino, Simona Golič Grdadolnik, Primož Šket, Janez Plavec, Daniela Iaconis, Vincenzo Summa, Francesca Esposito, Enzo Tramontano, Maria Monti, Andrea R. Beccari, , Andrea Zaliani
The paper identifies CPI-169 as a competitive inhibitor of SARS-CoV-2 PLpro that targets the same binding site as GRL-0617, through a drug repurposing screening approach that accounts for redox-sensitivity.
bioRxiv · Oct 11, 2023 · PreprintMolecular Biology